BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 7844602)

  • 1. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
    Merrouche Y; Negrier S; Bain C; Combaret V; Mercatello A; Coronel B; Moskovtchenko JF; Tolstoshev P; Moen R; Philip T
    J Clin Oncol; 1995 Feb; 13(2):410-8. PubMed ID: 7844602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.
    Rosenberg SA; Aebersold P; Cornetta K; Kasid A; Morgan RA; Moen R; Karson EM; Lotze MT; Yang JC; Topalian SL
    N Engl J Med; 1990 Aug; 323(9):570-8. PubMed ID: 2381442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
    Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
    Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of gene-marked tumor infiltrating lymphocytes from post-treatment biopsies: a case study.
    Aebersold P; Kasid A; Rosenberg SA
    Hum Gene Ther; 1990; 1(4):373-84. PubMed ID: 1964094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M; Rosenberg SA
    Cancer Res; 1993 Aug; 53(15):3561-8. PubMed ID: 8101762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients.
    Ridolfi R; Flamini E; Riccobon A; De Paola F; Maltoni R; Gardini A; Ridolfi L; Medri L; Poletti G; Amadori D
    Cancer Immunol Immunother; 1998 Jun; 46(4):185-93. PubMed ID: 9671141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrovirus-mediated gene transfer into CD4+ and CD8+ human T cell subsets derived from tumor-infiltrating lymphocytes and peripheral blood mononuclear cells.
    Morecki S; Karson E; Cornetta K; Kasid A; Aebersold P; Blaese RM; Anderson WF; Rosenberg SA
    Cancer Immunol Immunother; 1991; 32(6):342-52. PubMed ID: 2007247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial.
    Economou JS; Belldegrun AS; Glaspy J; Toloza EM; Figlin R; Hobbs J; Meldon N; Kaboo R; Tso CL; Miller A; Lau R; McBride W; Moen RC
    J Clin Invest; 1996 Jan; 97(2):515-21. PubMed ID: 8567975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human gene transfer: characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man.
    Kasid A; Morecki S; Aebersold P; Cornetta K; Culver K; Freeman S; Director E; Lotze MT; Blaese RM; Anderson WF
    Proc Natl Acad Sci U S A; 1990 Jan; 87(1):473-7. PubMed ID: 2404283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations.
    Whiteside TL
    In Vivo; 1991; 5(6):553-9. PubMed ID: 1810438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.
    Belldegrun A; Tso CL; Kaboo R; Pang S; Pierce W; deKernion JB; Figlin R
    J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):149-61. PubMed ID: 8732698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.
    Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO
    Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of gene therapy for the treatment of cancer.
    Rosenberg SA; Anderson WF; Blaese M; Hwu P; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Ettinghausen SE
    Ann Surg; 1993 Oct; 218(4):455-63; discussion 463-4. PubMed ID: 8215637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications of the polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells.
    Morgan RA; Cornetta K; Anderson WF
    Hum Gene Ther; 1990; 1(2):135-49. PubMed ID: 1964093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
    Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for gene therapy and lymphokine therapy for metastatic melanoma.
    Sivanandham M; Scoggin SD; Sperry RG; Wallack MK
    Ann Plast Surg; 1992 Jan; 28(1):114-8. PubMed ID: 1642399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.